Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

被引：0
|
作者：
Heinz Reichmann
Andrew Lees
José-Francisco Rocha
Diogo Magalhães
Patrício Soares-da-Silva
机构：
[1] University of Dresden,Department of Neurology
[2] Reta Lila Weston Institute,University College London
[3] BIAL – Portela & CA S.A,Global Parkinson’s Disease Department
[4] BIAL – Portela & CA S. A,Research and Development Department
[5] da Siderurgia Nacional,Department of Pharmacology and Therapeutics
[6] Faculty of Medicine,MedInUP, Center for Drug Discovery and Innovative Medicines
[7] University Porto,undefined
[8] University Porto,undefined
来源：
Translational Neurodegeneration | / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [31] Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study
    Jost, Wolfgang
    Reichmann, Heinz
    Lees, Andrew
    Marinho, Daniela
    Magalhaes, Diogo
    Rocha, Jose
    Soares-Da-Silva, Patricio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 272 - 272
  • [32] Opicapone for motor fluctuations in Parkinson's disease
    Devos, David
    Moreau, Caroline
    LANCET NEUROLOGY, 2016, 15 (02) : 127 - 128
  • [33] 1-year safety of opicapone in patients with Parkinson's disease and motor fluctuations
    Lees, A.
    Ferreira, J.
    Costa, R.
    Oliveira, C.
    Pinto, R.
    Lopes, N.
    Nunes, T.
    Rocha, J. F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2015, 30 : S99 - S99
  • [34] Opicapone analysis of health economic costs in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study
    Lees, Andrew
    Reichmann, Heinz
    Magalhaes, Diogo
    Rocha, Jose
    Soares-Da-Silva, Patricio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 277 - 278
  • [35] Opicapone improves global non-motor symptoms burden in Parkinson's disease: an open-label prospective study
    Santos Garcia, D.
    Fernandez Pajarin, G.
    Oropesa Ruiz, J.
    Escamilla Sevilla, F.
    Rahim Lopez, R.
    Munoz Enriquez, G.
    MOVEMENT DISORDERS, 2022, 37 : S350 - S351
  • [36] Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
    Lees, A.
    Reichmann, H.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2021, 36 : S218 - S219
  • [37] Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study
    Santos Garcia, Diego
    Fernandez Pajarin, Gustavo
    Manuel Oropesa-Ruiz, Juan
    Escamilla Sevilla, Francisco
    Rahim Lopez, Raul Rashid Abdul
    Munoz Enriquez, Jose Guillermo
    BRAIN SCIENCES, 2022, 12 (03)
  • [38] One-year open-label efficacy and safety of opicapone in Parkinson's disease BIPARK-II study
    Costa, R.
    Oliveira, C.
    Pinto, R.
    Lopes, N.
    Nunes, T.
    Rocha, J. -F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2014, 29 : S233 - S233
  • [39] Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Stocchi, F.
    Antonini, A.
    Moreira, J.
    Guimaraes, B.
    Rocha, J. F.
    MOVEMENT DISORDERS, 2023, 38 : S22 - S23
  • [40] Efficacy and safety of opicapone in patients over 70 years with Parkinson's disease and motor fluctuations
    Lees, A.
    Ferreira, J.
    Lopes, N.
    Costa, R.
    Santos, A.
    Oliveira, C.
    Pinto, R.
    Nunes, T.
    Rocha, J. F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2015, 30 : S99 - S99
12345